PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
Status:
Terminated
Trial end date:
2021-09-21
Target enrollment:
Participant gender:
Summary
This is a Phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate
the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or
without cancer.